4962 results
-
List item
Human medicine European public assessment report (EPAR): Zokinvy (updated)
Lonafarnib, Progeria; Laminopathies
Date of authorisation: 18/07/2022,
, 
, 
, Revision: 1, Authorised, Last updated: 24/03/2023
-
List item
Human medicine European public assessment report (EPAR): Azopt (updated)
brinzolamide, Glaucoma, Open-Angle; Ocular Hypertension
Date of authorisation: 09/03/2000, Revision: 27, Authorised, Last updated: 24/03/2023 -
List item
Human medicine European public assessment report (EPAR): Taxotere (updated)
docetaxel, Head and Neck Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Prostatic Neoplasms; Stomach Neoplasms; Breast Neoplasms
Date of authorisation: 27/11/1995, Revision: 50, Authorised, Last updated: 24/03/2023 -
List item
Human medicine European public assessment report (EPAR): Myocet liposomal (previously Myocet) (updated)
doxorubicin hydrochloride, Breast Neoplasms
Date of authorisation: 13/07/2000, Revision: 24, Authorised, Last updated: 24/03/2023 -
List item
Human medicine European public assessment report (EPAR): Tamiflu (updated)
oseltamivir, Influenza, Human
Date of authorisation: 20/06/2002, Revision: 42, Authorised, Last updated: 24/03/2023 -
List item
Human medicine European public assessment report (EPAR): Miglustat Dipharma (updated)
miglustat, Gaucher Disease
Date of authorisation: 18/02/2019,
, Revision: 5, Authorised, Last updated: 24/03/2023
-
List item
Human medicine European public assessment report (EPAR): Brukinsa (updated)
zanubrutinib, Waldenstrom Macroglobulinemia
Date of authorisation: 22/11/2021,, Revision: 5, Authorised, Last updated: 24/03/2023
-
List item
Human medicine European public assessment report (EPAR): Truvelog Mix 30 (updated)
insulin aspart, Diabetes Mellitus
Date of authorisation: 25/04/2022,, 
, Revision: 1, Authorised, Last updated: 23/03/2023
-
List item
Human medicine European public assessment report (EPAR): Terrosa (updated)
teriparatide, Osteoporosis
Date of authorisation: 04/01/2017,, , Revision: 6, Authorised, Last updated: 23/03/2023
-
List item
Human medicine European public assessment report (EPAR): Upstaza (updated)
Eladocagene exuparvovec, Amino Acid Metabolism, Inborn Errors
Date of authorisation: 18/07/2022,, , , Revision: 3, Authorised, Last updated: 23/03/2023
-
List item
Human medicine European public assessment report (EPAR): Dupixent (updated)
dupilumab, Dermatitis, Atopic; Prurigo; Esophageal Diseases; Asthma; Sinusitis
Date of authorisation: 26/09/2017, Revision: 25, Authorised, Last updated: 23/03/2023 -
List item
Human medicine European public assessment report (EPAR): MabThera (updated)
rituximab, Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 02/06/1998, Revision: 58, Authorised, Last updated: 22/03/2023 -
List item
Human medicine European public assessment report (EPAR): Ocrevus (updated)
ocrelizumab, Multiple Sclerosis
Date of authorisation: 08/01/2018, Revision: 16, Authorised, Last updated: 22/03/2023 -
List item
Human medicine European public assessment report (EPAR): Kadcyla (updated)
trastuzumab emtansine, Breast Neoplasms
Date of authorisation: 15/11/2013, Revision: 15, Authorised, Last updated: 22/03/2023 -
List item
Human medicine European public assessment report (EPAR): Vegzelma (updated)
bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 17/08/2022,, , Revision: 2, Authorised, Last updated: 22/03/2023
-
List item
Human medicine European public assessment report (EPAR): Polivy (updated)
polatuzumab vedotin, Lymphoma, B-Cell
Date of authorisation: 16/01/2020,, , 
, Revision: 5, Authorised, Last updated: 22/03/2023
-
List item
Human medicine European public assessment report (EPAR): Elebrato Ellipta (updated)
fluticasone furoate, umeclidinium bromide, vilanterol trifenatate, Pulmonary Disease, Chronic Obstructive
Date of authorisation: 15/11/2017, Revision: 11, Authorised, Last updated: 22/03/2023 -
List item
Human medicine European public assessment report (EPAR): Suliqua (updated)
insulin glargine, lixisenatide, Diabetes Mellitus, Type 2
Date of authorisation: 11/01/2017, Revision: 10, Authorised, Last updated: 22/03/2023 -
List item
Human medicine European public assessment report (EPAR): Trelegy Ellipta (updated)
fluticasone furoate, umeclidinium bromide, vilanterol trifenatate, Pulmonary Disease, Chronic Obstructive
Date of authorisation: 15/11/2017, Revision: 10, Authorised, Last updated: 22/03/2023 -
List item
Human medicine European public assessment report (EPAR): Pradaxa (updated)
Dabigatran etexilate mesilate, Arthroplasty, Replacement; Venous Thromboembolism
Date of authorisation: 17/03/2008, Revision: 39, Authorised, Last updated: 22/03/2023 -
List item
Human medicine European public assessment report (EPAR): Zynlonta (updated)
loncastuximab tesirine, Lymphoma, Large B-Cell, Diffuse; Lymphoma, B-Cell
Date of authorisation: 20/12/2022,, , Revision: 1, Authorised, Last updated: 22/03/2023
-
List item
Human medicine European public assessment report (EPAR): Simponi (updated)
Golimumab, Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid
Date of authorisation: 01/10/2009, Revision: 44, Authorised, Last updated: 22/03/2023 -
List item
Human medicine European public assessment report (EPAR): Hexacima (updated)
hepatitis B surface antigen, Diphtheria toxoid, tetanus toxoid, Bordetella pertussis antigens Pertussis Toxoid Filamentous Haemagglutinin, poliovirus (inactivated) type 1 (Mahoney) type 2 (MEF-1) type 3 (Saukett), Haemophilus influenzae type b polysaccharide (Polyribosylribitol Phosphate) conjugated to Tetanus protein, Hepatitis B; Tetanus; Immunization; Meningitis, Haemophilus; Whooping Cough; Poliomyelitis; Diphtheria
Date of authorisation: 17/04/2013,
Date of refusal: 22/02/2013, Revision: 28, Authorised, Last updated: 22/03/2023 -
List item
Human medicine European public assessment report (EPAR): NovoRapid (updated)
insulin aspart, Diabetes Mellitus
Date of authorisation: 07/09/1999, Revision: 32, Authorised, Last updated: 22/03/2023 -
List item
Human medicine European public assessment report (EPAR): Blincyto (updated)
blinatumomab, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Date of authorisation: 23/11/2015,, , Revision: 16, Authorised, Last updated: 22/03/2023